Author(s): A. Raja Reddy, R. Devicharan, T. Rama Rao

Email(s): rajareddyaleti050@gmail.com

DOI: : 10.52711/0974-360X.2023.00614   

Address: A. Raja Reddy, R. Devicharan, T. Rama Rao
Department of Pharmaceutical Analysis CMR College of Pharmacy, Kandlakoya, Medchal, India-501401.
*Corresponding Author

Published In:   Volume - 16,      Issue - 8,     Year - 2023


ABSTRACT:
The Emtricitabine, Bictegravir and Tenofovir are used to treat Cystic fibrosis treatment. For estimation of this drug in bulk and pharmaceutical dosage form the standard, simple, accurate RP-HPLC method was devoloped, to run the sample column used was Kromasil C18 150×4.6mm,5µ and mobile phase of 0.1%OPA and acetonitrile of 55:45 v/v at a flow rate of 1ml/min, 30°C temperature was maintained, 272.0 nm wavelength was used. The retention times for tenofovir, bictegravir, and emtricitabine were 2.140,2.432, and 2.992 minutes, respectively. Emtricitabine, Bictegravir, and Tenofovir were found to have 1.1, 1.0, and 0.9 percent RSD of method precision respectively. Emtricitabine, Bictegravir, and Tenofovir all recovered 100.24 percent, 100.19 percent, and 100.06 percent of their doses, respectively and LOQ values are 0.93 ppm, 0.34 ppm and 0.23ppm respectively, and LOQ values are 2.80ppm, 1.04, 0.70ppm, respectively, for Emtricitabine, Bictegravir, and Tenofovir.


Cite this article:
A. Raja Reddy, R. Devicharan, T. Rama Rao. Analytical RP-HPLC method development and validation for simultaneous estimation of Emtricitabine, Tenofovir and Bictegravir. Research Journal of Pharmacy and Technology 2023; 16(8):3722-6. doi: : 10.52711/0974-360X.2023.00614

Cite(Electronic):
A. Raja Reddy, R. Devicharan, T. Rama Rao. Analytical RP-HPLC method development and validation for simultaneous estimation of Emtricitabine, Tenofovir and Bictegravir. Research Journal of Pharmacy and Technology 2023; 16(8):3722-6. doi: : 10.52711/0974-360X.2023.00614   Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-8-34


REFERENCES:
1.    https://go.drugbank.com/drugs/DB00879
2.    https://go.drugbank.com/drugs/DB11799
3.    https://go.drugbank.com/drugs/DB14126
4.    Bhushan P. Badgujar, Moreshwar P. Mahajan et al. Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Tenofovir Alafenamide and Emtricitabine in Bulk and Tablet Dosage Form. International Journal of ChemTech Research. 2017; 10 (5): 731-739
5.    VVSS. Appala Raju et al. Bioanalytical Method Development And Validation For Simultaneous Determination Of Bictegravir, Tenofovir And Emtricitabine In Human Plasma By LCMS/MS. WJPPS. 2018; 7, (12).
6.    Vasanti M. Suvarna et al. Development And Validation Of Stability Indicating Rp-Hplc Method For Tenofovir Solid Lipid Nanoparticles. Int J Pharm Sci Res. 2017; 8(2): 658-66.
7.    Yenumula BRR, Singampalli MR, Challa BSR. Simultaneous Estimation of Emtricitabine and Tenofovir Disoproxil Fumarate in Tablet Dosage Form by Reverse Phase Highperformance Liquid Chromatography. SOJ Chromatograph Sci. 2015;1:6), doi:10.15226/2471-3627/1/1/00105.
8.    Sharma R, Gupta P. A Validated RP-HPLC Method for Simulataneous Estimation of Emtricitabine and Tenofovir Disoproxil Fumarate in a Tablet Dosage Form. Eurasian J Anal Chem. 2009; 4(3):276–284.
9.    Shelke A, Shinde M, Mogal R, et al. Application of UV Spectrophotometric methods for simultaneous estimation of Emtricitabine and Tenofovir alafenamide fumarate in bulk. Asian J Pharm Techn. 2018; 8: 2231–5713.
10.    Snyder RL, kirklannd JJ, Glaijch LJ. Practical HPLC [reverse phase high performance liquid chromatography] method development. 2nd ed. New York: Wiley; 1997. p. 30–100.
11.    Satinder A, Dong MW. Method development and validation.pharmaceutical analysis by HPLC [reverse phase high performance liquid chromatography]. Vol. 6. Newyork: Elsevier; 2005. p. 16–70.
12.    Swartz ME, Krull I. Analytical method development and validation. 1st ed. New York: Marcel Dekker; 2009. p. 17–80

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank

Journal Policies & Information


Recent Articles




Tags


Not Available